Edaravone

(Radicava®)

Edaravone

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 30 mg/100 mL); Suspension (oral; 105 mg/5 mL)
Drug ClassAntioxidants
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review/meta-analysis. [1]
  • Intravenous edaravone showed a statistically significant improvement in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score compared to placebo, with a mean difference of 1.63 (95% confidence interval (CI): 0.26-3.00, p = 0.02) at 24 weeks, indicating potential efficacy in amyotrophic lateral sclerosis patients.
  • No significant differences were observed in the frequency of adverse events (odds ratio (OR): 1.22, 95% CI: 0.68-2.19, p = 0.50) or serious adverse events (OR: 0.71, 95% CI: 0.43-1.19, p = 0.20) between the edaravone and placebo groups, suggesting a favorable safety profile for edaravone.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Radicava (edaravone) Prescribing Information.2022Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Canadian best practice recommendations for the management of amyotrophic lateral sclerosis2020Canadian Medical Association Journal